认知障碍人群的干预设计:OPTIMIZE 减处方实用试验的经验教训
本研究基于 OPTIMIZE 减处方实用试验,通过定性访谈和调查(15 例患者、7 名照护者、28 名临床医生)探讨在认知障碍老年人中实施减处方干预的可接受性与挑战。结果显示所有利益相关群体均认可干预的可接受性、重要性和实施,但干预材料的回忆不一致,且就诊时间短是医生减处方的最大障碍。研究强调干预实施中时机与重复的关键作用。
要点
- 认知障碍老年人及其照护者和临床医生均认可减处方干预的可接受性与重要性。
- 干预材料回忆不一致,短时就诊是医生实施减处方的最大障碍。
- 干预实施的时机与重复对认知障碍人群至关重要。
核心结论
- 在认知障碍老年人中实施减处方干预具有可接受性,但需重视干预时机与重复,并克服短时就诊的障碍。
研究设计与样本
- 基于 OPTIMIZE 减处方实用试验的事后定性访谈与调查,纳入 15 例患者、7 名照护者和 28 名临床医生。
主要发现
- 干预接受度受认知、既往减处方知识、沟通和时间限制等情境因素影响。
- 所有利益相关群体均认可干预的可接受性、重要性和实施。
- 积极影响机制包括患者预约专门讨论减处方和医生被提示考虑减处方。
- 干预材料回忆不一致,但最可能在干预实施后不久回忆。
- 短时就诊仍是医生减处方的最大障碍。
临床怎么用
- 可将减处方教育纳入常规临床实践,并注重干预实施的时机与重复。
- 针对认知障碍老年人,需关注短时就诊对减处方实施的阻碍。
局限性
- 本研究为事后定性访谈与调查,样本量有限(15 例患者、7 名照护者、28 名临床医生)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polypharmacy is common in older adults with cognitive impairment and multiple chronic conditions, increasing risks of adverse drug events, hospitalization, and death. Deprescribing, the process of reducing or stopping potentially inappropriate medications, may improve outcomes. The OPTIMIZE pragmatic trial examined whether educating and activating patients, family members and clinicians about deprescribing reduces number of chronic medications and potentially inappropriate medications. Acceptability and challenges of intervention delivery in cognitively impaired older adults are not well understood. METHODS: We explored mechanisms of intervention implementation through post hoc qualitative interviews and surveys with stakeholder groups of 15 patients, 7 caregivers, and 28 clinicians. We assessed the context in which the intervention was delivered, its implementation, and mechanisms of impact. RESULTS: Acceptance of the intervention was affected by contextual factors including cognition, prior knowledge of deprescribing, communication, and time constraints. All stakeholder groups endorsed the acceptability, importance, and delivery of the intervention. Positive mechanisms of impact included patients scheduling specific appointments to discuss deprescribing and providers being prompted to consider deprescribing. Recollection of intervention materials was inconsistent but most likely shortly after intervention delivery. Short visit times remained the largest provider barrier to deprescribing. CONCLUSIONS: Our work identifies key learnings in intervention delivery that can guide future scaling of deprescribing interventions in this population. We highlight the critical roles of timing and repetition in intervention delivery to cognitively impaired populations and the barrier posed by short consultation times. The acceptability of the intervention to patients and family members highlights the potential to incorporate deprescribing education into routine clinical practice and expand proven interventions to other vulnerable populations.
引用
- Sheehan OC, Gleason KS, Bayliss EA, et al. Intervention design in cognitively impaired populations-Lessons learned from the OPTIMIZE deprescribing pragmatic trial. J Am Geriatr Soc. 2022. PMID: 36508725. doi:10.1111/jgs.18148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。